true. been a long time holder but havent really commented for years. i always wanted the distribution to be handled by someone else and its great now to have a fixed profit margin and reduced overheads. the capital raising for non-R&D expenditure (primarily wages) was the cause of so much dilution. Now we can concentrate on manufacturing and R&D and have a leaner operation. this is a good step to improving cashflow. the recent order (albeit including stock at the time of sale) will add further to the coffers. if this order is planned for a years worth of sales, then Wayne can more easily set a scenario that is less likely to need a raise. budget and forecast with more accuracy.
Id like to know the following if an y of you know:
1 - how staff break cost affected cashflow in the previous
two quarters and whats left to come
2 - what other divestment costs are there (breaking leases, office write offs).
3 - what is the marketing requirements from this distribution sale? all the global conference? the trial doctors? etc. who is responsible for drumming up these costs? im sure its contracted
4 - what costs are included/excluded from the 20% margin? what was our equivalent margin on ssles over the previous 6/12 months?
5 - what operational cost savings can we expect from the divestment?
im certainly feeling better about AHZ but until im clear on the above then i wont sure cashflow can/will be managed.
- Forums
- ASX - By Stock
- Ann: SAVR Clinical Trial
true. been a long time holder but havent really commented for...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$15.30 |
Change
0.150(0.99%) |
Mkt cap ! $294.1M |
Open | High | Low | Value | Volume |
$15.35 | $15.35 | $15.00 | $92.29K | 6.09K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 50 | $15.20 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.30 | 276 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50 | 15.200 |
1 | 39 | 15.040 |
1 | 1000 | 15.000 |
1 | 756 | 14.950 |
1 | 300 | 14.900 |
Price($) | Vol. | No. |
---|---|---|
15.300 | 276 | 1 |
15.700 | 277 | 1 |
15.880 | 250 | 1 |
16.000 | 100 | 1 |
16.030 | 999 | 1 |
Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online